Rate of Response of Individual Asthma Control Measures Varies and May Overestimate Asthma Control: An Analysis of the Goal Study

Background: Using a composite measure based on clinical outcomes, the GOAL study showed that achievement of Total Control of asthma was time dependent with the proportion of controlled patients continuing to rise through the year-long study. Taking data from this study, we compared time taken to achieve Total Control with time taken to achieve total control of each individual clinical criterion on treatment with salmeterol/fluticasone propionate (SFC) or fluticasone propionate (FP) alone. Methods: Time to achieving total control of individual outcomes (day-time symptoms, night-time awakenings, rescue medication use, PEF ≥80% predicted every day) were analyzed by Kaplan Meier plots and compared with achievement of composite Total Control. Results: Night-time awakenings responded most rapidly and daytime symptoms took longest to respond. After 12 weeks, the proportion of patients who achieved control of any individual clinical criterion was higher than the proportion who achieved control when using the composite outcome (no night-time awakenings achieved by 73% with SFC and 65% with FP; PEF ≥80% predicted every day, 55% and 45% respectively; no rescue usage 46% and 35% respectively; and no daytime symptoms, 35% and 24% respectively, compared with Total Control, 23% and 14% respectively). In every measure except night-time awakenings, more rapid responses were seen for SFC compared with FP alone. Conclusions: Speed of response of individual asthma measures varies and evaluation of control using any single measure overestimates total asthma control. Treatment should be continued until composite control is reached, rather than control of individual outcomes.

[1]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[2]  C. Jenkins,et al.  Traditional and patient-centred outcomes with three classes of asthma medication , 2005, European Respiratory Journal.

[3]  G. Guyatt,et al.  A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  Philip Marcus,et al.  Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.

[5]  K. Chung,et al.  Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. , 1998, Thorax.

[6]  C. Jenkins,et al.  When can personal best peak flow be determined for asthma action plans? , 2004, Thorax.

[7]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[8]  C. Jenkins,et al.  Optimal asthma control, starting with high doses of inhaled budesonide. , 2000, The European respiratory journal.

[9]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[10]  British guideline on the management of asthma. , 2003, Thorax.

[11]  D. Johns,et al.  Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma , 2002, Thorax.

[12]  A. Woolcock,et al.  What are the important questions in the treatment of asthma , 2001 .

[13]  J. Malo,et al.  Patterns of improvement in spirometry, bronchial hyperresponsiveness, and specific IgE antibody levels after cessation of exposure in occupational asthma caused by snow-crab processing. , 1988, The American review of respiratory disease.

[14]  P. Barnes,et al.  Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids , 2002, European Respiratory Journal.

[15]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[16]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[17]  H. Nelson,et al.  Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. , 2001, The Journal of allergy and clinical immunology.

[18]  R. Hancox,et al.  The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. , 2001, American journal of respiratory and critical care medicine.

[19]  F. Hargreave,et al.  A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. , 2000, The Journal of allergy and clinical immunology.

[20]  J. Vandenbroucke,et al.  Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. , 1999, American journal of respiratory and critical care medicine.

[21]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[22]  J. Cowan,et al.  Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. , 2005, The New England journal of medicine.